N/A N=1 Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use
Stress Urinary Incontinence
Primary: Study-Related Adverse Events — 0 Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=46 Cytokine Removal in Cardiopulmonary Bypass Patients
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
Phase 3 N=357 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Subjects With Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) <= 3.2 at Week 104 in RA0055 Period 2 Without Flaring — 39.2; 53.2…
N/A N=304 ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Phase I: Number of Participants With Demographic Characteristics in Monotherapy and Combination Therapy — 79; 75; 73; 77 Participants
Phase 2 N=21 Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
Lupus Nephritis
Primary: Complete and Partial Response Rate — 55 Percentage of participants
Phase 2 N=100 Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 98.0; 70.7; 100.0 Percentage of participants
Phase 2 N=60 Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents
Tuberculosis
Primary: Number of Subjects With Solicited Local Symptoms — 37; 3; 3; 0 Subjects
N/A N=277 Remote Access to Care, Everywhere, for Parkinson Disease
Parkinson Disease
Primary: Feasibility — 91 percentage of visits
Phase 4 N=12 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder
Bipolar Disorder · Alcoholism · Alcohol Dependence
Primary: Amount of Alcohol Consumed — -1.38; -0.69 number of drinks per heavy drinking day
Phase 2 N=180 The Safety And Efficacy Of Maintenance Therapy With CP-690,550
Crohn's Disease
Primary: Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or…
Phase 3 N=716 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
Rubella · Varicella · Measles
Primary: Number of Seroconverted Subjects for Measles, Mumps, Rubella, and Varicella Virus — 305; 162; 292; 151 Participants
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35
N/A N=147,716 Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke
Ischemic Stroke
Primary: Number of Participants Receiving Inpatient, Home, or Community Based Rehabilitation Services — 76720; 32350 participants
N/A N=101 The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes
Diabetes Mellitus, Type 2 · Medication Adherence · HYPERGLYCEMIA
Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin
Phase 3 N=2,279 Promoting Heart Health in Preschool Children
Cardiovascular Health
Primary: Change in KAH Score for Children — 7.66; 3.76 units on a scale — p=<.001